We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Noninvasive Diagnostic Test Indicates Preterm Birth Risk

By HospiMedica staff writers
Posted on 24 Apr 2007
Cervical-vaginal fluid (CVF) is a potential rich source of biomarkers for enhancing our understanding of human parturition and pathologic conditions affecting pregnancy.
Scientists have performed a comprehensive survey of the CVF proteome in pregnancy utilizing multidimensional liquid chromatography (2D-LC) coupled with mass spectrometry and gel-electrophoresis-based protein separation and identification. More...


In total, 150 unique proteins were identified using multiple protein identification algorithms. Metabolism (32%) and immune response-related (22%) proteins are the major functional categories represented in the CVF proteome. A comparison of the CVF, serum, and amniotic fluid proteomes showed that 77 proteins are unique to CVF, while 56 and 17 CVF proteins also occur in serum and amniotic fluid, respectively. This data set provides a foundation for evaluation of these proteins as potential CVF biomarkers for noninvasive diagnosis of pregnancy-related disorders.

With pre-term births a major international health problem, scientists are reporting an advance toward developing a much-needed, noninvasive test for predicting when pregnant women are about to deliver early. Oregon Health Science University's (Portland, OR, USA) Dr. Srinivasa R. Nagalla and colleagues there and at the University of Washington in Seattle, WA, USA, reported the discovery of protein biomarkers that could lead to such a test. The work was published in the April 9, 2007, issue of the Journal of Proteome Research.

In the report, researchers explained that spontaneous preterm births (before 37 weeks of pregnancy) have increased steadily during the last 25 years and now account for 70-80% of neonatal deaths. Development of a rapid diagnostic test for pre-term labor would be a major advance.

The scientists analyzed cervical-vaginal fluid from 18 women, including six with spontaneous preterm birth, six with preterm labor, and six controls. They identified proteins that were present in women with preterm deliveries that could eventually serve as biomarkers for the condition. While emphasizing that the finding should be confirmed in a larger group of women, the study terms it an important step toward identifying women at high risk for preterm birth.


Related Links:
Oregon Health Science University

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.